Brookstone Capital Management Increases Stake in Becton, Dickinson and Company $BDX

Brookstone Capital Management lifted its stake in Becton, Dickinson and Company (NYSE:BDX) by 9.2% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 19,500 shares of the medical instruments supplier’s stock after purchasing an additional 1,650 shares during the quarter. Brookstone Capital Management’s holdings in Becton, Dickinson and Company were worth $3,359,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Saudi Central Bank purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $26,000. Smallwood Wealth Investment Management LLC purchased a new position in shares of Becton, Dickinson and Company in the 1st quarter valued at approximately $27,000. Alpine Bank Wealth Management acquired a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $29,000. Cornerstone Planning Group LLC increased its holdings in Becton, Dickinson and Company by 341.4% in the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier’s stock worth $29,000 after buying an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA acquired a new position in Becton, Dickinson and Company in the 1st quarter worth approximately $31,000. 86.97% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of Becton, Dickinson and Company stock in a transaction on Wednesday, September 10th. The shares were sold at an average price of $187.50, for a total value of $171,937.50. Following the sale, the director owned 22,226 shares of the company’s stock, valued at approximately $4,167,375. This trade represents a 3.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last 90 days, insiders have sold 1,838 shares of company stock valued at $348,392. 0.36% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on BDX. Piper Sandler reiterated a “neutral” rating and issued a $200.00 price target (up previously from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley increased their price target on shares of Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an “overweight” rating in a report on Monday, August 11th. Argus increased their price target on shares of Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Wells Fargo & Company increased their price target on shares of Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an “equal weight” rating in a report on Friday, August 8th. Finally, Weiss Ratings reiterated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $205.40.

Becton, Dickinson and Company Price Performance

Shares of NYSE BDX opened at $186.62 on Friday. The stock has a market capitalization of $53.49 billion, a price-to-earnings ratio of 33.56, a PEG ratio of 1.47 and a beta of 0.25. Becton, Dickinson and Company has a 12 month low of $163.33 and a 12 month high of $251.99. The firm’s 50 day simple moving average is $190.13 and its 200-day simple moving average is $184.19. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.10 and a quick ratio of 0.62.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings data on Thursday, April 14th. The medical instruments supplier reported $4.10 EPS for the quarter. Becton, Dickinson and Company had a net margin of 7.51% and a return on equity of 16.23%. The business had revenue of $5.32 billion for the quarter. Analysts expect that Becton, Dickinson and Company will post 14.43 EPS for the current year.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.